Aerovate Therapeutics (AVTE) Competitors $11.14 +0.34 (+3.15%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. NAGE, AUPH, ELVN, ABCL, WVE, VERV, PAHC, AKBA, COLL, and NTLAShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Niagen Bioscience (NAGE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Niagen Bioscience Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics WAVE Life Sciences Verve Therapeutics Phibro Animal Health Akebia Therapeutics Collegium Pharmaceutical Intellia Therapeutics Niagen Bioscience (NASDAQ:NAGE) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Which has more volatility and risk, NAGE or AVTE? Niagen Bioscience has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Which has preferable earnings and valuation, NAGE or AVTE? Niagen Bioscience has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$99.60M10.05$8.55M$0.1774.76Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-6.55 Does the media prefer NAGE or AVTE? In the previous week, Niagen Bioscience had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Niagen Bioscience and 0 mentions for Aerovate Therapeutics. Niagen Bioscience's average media sentiment score of 0.22 beat Aerovate Therapeutics' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Overall Sentiment Niagen Bioscience Neutral Aerovate Therapeutics Neutral Do analysts rate NAGE or AVTE? Niagen Bioscience currently has a consensus price target of $19.50, suggesting a potential upside of 53.42%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Niagen Bioscience is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NAGE or AVTE more profitable? Niagen Bioscience has a net margin of 13.07% compared to Aerovate Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 19.06% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience13.07% 19.06% 12.20% Aerovate Therapeutics N/A -90.19%-77.47% Do institutionals and insiders have more ownership in NAGE or AVTE? 15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryNiagen Bioscience beats Aerovate Therapeutics on 14 of the 15 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$322.89M$812.96M$5.56B$9.05BDividend YieldN/A4.84%5.24%3.99%P/E Ratio-3.731.1519.9620.26Price / SalesN/A230.41419.56119.26Price / CashN/A23.4426.2128.59Price / Book2.816.328.035.65Net Income-$75.52M-$27.99M$3.18B$249.15M7 Day Performance21.22%2.10%2.93%3.28%1 Month Performance61.68%9.39%1.72%3.95%1 Year Performance-80.23%11.51%34.39%20.98% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$11.14+3.1%N/A-80.2%$322.89MN/A-3.7320High Trading VolumeNAGENiagen Bioscience1.3093 of 5 stars$13.64+1.5%$19.50+43.0%+406.4%$1.06B$99.60M80.24120AUPHAurinia Pharmaceuticals3.0711 of 5 stars$7.83+0.8%$11.50+46.9%+34.9%$1.05B$235.13M27.96300ELVNEnliven Therapeutics2.6798 of 5 stars$20.29-4.7%$39.60+95.2%-7.8%$1.05BN/A-10.5750Analyst ForecastAnalyst RevisionHigh Trading VolumeABCLAbCellera Biologics2.4588 of 5 stars$3.33-2.3%$8.33+150.3%+41.4%$1.02B$28.83M-5.95500WVEWAVE Life Sciences4.4456 of 5 stars$6.96+5.9%$20.50+194.5%+27.4%$1.01B$108.30M-8.29240News CoverageVERVVerve Therapeutics3.4842 of 5 stars$11.11+0.5%$14.75+32.8%+113.8%$985.92M$32.33M-5.27110High Trading VolumePAHCPhibro Animal Health3.6446 of 5 stars$24.46+2.4%$20.80-15.0%+66.1%$967.94M$1.02B31.361,940AKBAAkebia Therapeutics4.2537 of 5 stars$3.64-1.1%$6.75+85.4%+285.3%$966.50M$160.18M-17.33430Insider TradeCOLLCollegium Pharmaceutical4.2655 of 5 stars$29.88+0.2%$43.75+46.4%-5.6%$958.49M$631.45M24.49210News CoverageAnalyst DowngradeNTLAIntellia Therapeutics4.7197 of 5 stars$9.23+0.3%$33.37+261.5%-52.9%$952.96M$57.88M-1.76600News Coverage Related Companies and Tools Related Companies Niagen Bioscience Competitors Aurinia Pharmaceuticals Competitors Enliven Therapeutics Competitors AbCellera Biologics Competitors WAVE Life Sciences Competitors Verve Therapeutics Competitors Phibro Animal Health Competitors Akebia Therapeutics Competitors Collegium Pharmaceutical Competitors Intellia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts